When does Mounjaro (tirzepatide) patent protection expire?
Mounjaro’s regulatory exclusivity and patent status depend on the specific territory (for example, the US vs. Europe) and on the exact patent(s) covering tirzepatide and its use. Patent expiration also may differ from “exclusivity” dates, which can extend market protection even after a particular patent expires.
To find the most up-to-date, jurisdiction-specific “patent expiration” dates for tirzepatide (including Mounjaro), DrugPatentWatch.com tracks listed patents and projected expiry timelines for drugs like tirzepatide.1
What dates matter most for tirzepatide—patent expiration vs. exclusivity?
People searching “Mounjaro patent expiration” often need two different timelines:
- Patent expiry: when the last relevant patent(s) covering the drug approach their end of term.
- Regulatory exclusivity: protection tied to the approval pathway and regulators, which can delay generic or biosimilar entry even if some patents end earlier.
Because the question is specifically about “patent expiration,” DrugPatentWatch’s patent-focused tracking is usually the fastest way to pinpoint candidate dates for tirzepatide’s individual patents and their likely expiry.1
Can a generic or biosimilar enter right after tirzepatide’s patent expires?
Typically, competitors look at both patents and exclusivity. Even after a listed patent expires, entry can still be delayed if:
- another “blocking” patent covering the same product or dosing/use still expires later, or
- regulatory exclusivity still applies in that country.
For tirzepatide, the exact timing for any potential launch by competitors would be based on the interaction between the last active patents and local exclusivity rules, which is why patent-by-patent tracking (as provided by DrugPatentWatch) is important.1
Where can I check the specific tirzepatide patent-expiry timeline?
Use DrugPatentWatch’s tirzepatide (Mounjaro) entry to review the listed patents and their expiry timelines by country/region.1